Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate

Journal of Neuro-Oncology

Volumn 41, Issue 2, 1999, Pages 107-116

  Boyle, Frances M ^a   Wheeler, Helen R ^a   Shenfield, Gillian M ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Cisplatin; Cytotoxicity; Glutamate; Neurotoxicity; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GLUTAMATE SODIUM; GLUTAMIC ACID; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DARKNESS; DRUG EFFICACY; FEMALE; GAIT; INTRAPERITONEAL DRUG ADMINISTRATION; LIGHT; MOTOR NEUROPATHY; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PROPRIOCEPTION; RAT; SENSORY NEUROPATHY; TAIL FLICK TEST;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CISPLATIN; FEMALE; GAIT; GLUTAMIC ACID; HEAT; MAMMARY NEOPLASMS, EXPERIMENTAL; MOTOR ACTIVITY; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; SENSORY THRESHOLDS;

EID: 0032950178     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006124917643     Document Type: Article

References (54)

1. Cersosimo RJ: Cisplatin neurotoxicity. Cancer Treat Rev 16: 195-211, 1989
2. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC: Neurotoxicity of taxol. Monogr Natl Cancer Inst 107-115, 1993
3. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N, Tredici G: Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75: 1141-1150, 1995
4. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR: Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35: 304-311, 1994
5. Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuchjacquotte A, Blum R, Speyer J: Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer - an active regimen with limiting neurotoxicity. J Clin Oncol 14: 1993-1999, 1996
6. Connelly E, Markman M, Kennedy A, Webster K, Kuip B, Peterson G, Belinson J: Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 62: 166-168, 1996
7. Rowinsky EK, Donehower RC: Paclitaxel (taxol). N Engl J Med 332: 1004-1014, 1995
8. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010-2020, 1993
9. Derry WB, Wilson L, Jordan MA: Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 34: 2203-2211, 1995
10. Freilich RI, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM: Motor neuropathy due to docetaxel and paclitaxel. Nutr Rev 47: 115-118, 1996
11. Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, Stewart DJ: Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10: 795-803, 1992
12. Barajon I, Bersani M, Quartu M, Del Fiacco M, Cavaletti G, Holst JJ, Tredici G: Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuropathy. Experimental Neurology 138: 93-104, 1996
13. Malgrange B, Delree P, Rigo JM, Baron H, Moonen G: Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. J Neurosci Methods 53: 111-122, 1994
14. Krarup-Hansen A, Fugleholm K, Helweg Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, Krarup C: Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain 116: 1017-1041, 1993
15. Hansen SW: Late-effects after treatment for germ-cell cancer with cisplatin, vinblastine, and bleomycin. Dan Med Bull 39: 391-399, 1992
16. Cavaletti G, Bogliun G, Marzorati L, Tredici G, Colombo N, Parma G, Miceli MD: Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res 14: 1287-1292, 1994
17. Schmalbruch H, Krarup C: Animal models of neuropathies. Baillieres Clinical Neurology 5: 77-105, 1996
18. Gerritsen van der Hoop R, Vecht CJ, van der Burg ME, Elderson A, Boogerd W, Heimans JJ, Vries EP, van Houwelingen JC, Jennekens FG, Gispen WH et al.: Prevention of cis-platin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 322: 89-94, 1990
19. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101-2112, 1996
20. Pirovano C, Balzarini A, Bohm S, Oriana S, Spatti GB, Zunino F: Peripheral neurotoxicity following high-dose cisplatin with glutathione: clinical and neurophysiological assessment. Tumori 78: 253-257, 1992
21. Apfel SC, Arezzo JC, Lipson L, Kessler JA: Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 31: 76-80, 1992
22. Apfel SC, Lipton RB, Arezzo JC, Kessler JA: Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 29: 87-90, 1991
23. Gao WQ, Dybdal N, Shinsky N, Murnane A, Schmelzer C, Siegel M, Keller G, Hefti F, Phillips HS, Winslow JW: Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 38: 30-37, 1995
24. Twentyman PR: Modification by WR 2721 of the response to chemotherapy of tumours and normal tissues in the mouse. Br J Cancer 47: 57-63, 1983
25. Kelland LR: New platinum antitumor complexes. Crit Rev Oncol-Hemat 15: 191-219, 1993
26. Jackson DV, Jr., Rosenbaum DL, Carlisle LJ, Long TR, Wells HB, Spurr CL: Glutamic acid modification of vincristine toxicity. Cancer Biochem Biophys 7: 245-252, 1984
27. Jackson DV, Wells HB, Atkins IN, Zekan PJ, White DR, Richards F, 2d, Cruz JM, Muss HB: Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 84: 1016-1022, 1988
28. Johnson IS, Wright HF, Svoboda GS, Vlantis J: Antitumor principles derived from vinca Rosea Linn. I. Vincaleukoblastine and Leurosine. Cancer Res 20: 1016-1022, 1960
29. Boyle FM, Wheeler HR, Shenfield GM: Glutamate ameliorates experimental vincristine neuropathy. J Pharm Exp Ther 279: 410-415, 1996
30. Boyle FM, Monk R, Wheeler H, Shenfield G: The experimental neuroprotectant glutamate does not inhibit cytotoxicity of vinca alkaloids, cisplatin or paclitaxel. Proc AACR 38: 607, 1997 (Abstract)
31. Dellon, AL: Somatosensory testing and rehabilitation. American Occupational Therapy Assoc, Bethesda, 1997
32. Coyle P, Rofe AM, Bourgeois CS, Conyers RA: Biochemical manifestations of a rat mammary adenocarcinoma-producing cachexia: in vivo and in vitro studies. Immunol Cell Biol 68: 147-153, 1990
33. Euhus DM, Hudd C, LaRegina MC, Johnson FE: Tumor measurement in the nude mouse. J Surg Oncol 31: 229-234, 1986
34. Sandier SG, Tobin W, Henderson ES: Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Nutr Rev 19: 367-374, 1969
35. Cavaletti E, Montaguti P, Oggioni N, Caveletti G, Tredici G: Peripheral neurotoxicity of intravenous Taxol in rats. Proc AACR 37: 375, 1996 (Abstract)
36. de Koning P, Neijt JP, Jennekens FG, Gispen WH: Evaluation of cis-diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats. Toxicol Appl Pharmacol 89: 81-87, 1987
37. Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR, Tredici G: Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 69: 203-207, 1992
38. Cavaletti G, Cascinu S, Venturino P, Tedeschi M, Tredici G: Neuroprotectant drugs in cisplatin neurotoxicity. Anticancer Res 16: 3149-3159, 1996
39. Journey U, Burdman J, Whaley A: Electron microscopic study of spinal ganglia from vincristine-treated mice. J Natl Cancer Inst 43: 603-619, 1969
40. Wisniewski H, Shelanski ML, Terry RD: Effects of mitotic spindle inhibitors on neurotubules and neuro filaments in anterior horn cells. J Cell Biol 38: 224-229, 1968
41. Boyle FM, Davey RA, Bell DR, Wheeler HR, Friedlander ML: Glutamic acid does not inhibit in vitro cytotoxicity of vinca alkaloids. Proc AACR 33: 424, 1992 (Abstract)
42. Lipton SA, Rosenberg PA: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330: 613-622, 1994
43. Pearce IA, Cambray-Deakin MA, Burgoyne RD: Glutamate acting on NMDA receptors stimulates neurite outgrowth from cerebellar granule cells. FEBS Lett 223: 143-147, 1987
44. Jones PG, Rosser SJ, Bulloch AGM: Glutamate enhancement of neurite outgrowth in Helisoma neurons. Soc Neurosci Abs 12: 509, 1986 (Abstract)
45. Lipton SA, Kater SB: Neurotransmitterregulation of neuronal outgrowth, plasticity and survival. Trends Neurosci 12: 265-270, 1989
46. Lovinger DM, Weight FF: Glutamate induces a depolarization of adult rat dorsal root ganglion neurons that is mediated predominantly by NMDA receptors. Neurosci Lett 94: 314-320, 1988
47. Daoud SS, Clements MK, Small CL: Polymerase chain reaction analysis of cisplatin-induced mitochondrial DNA damage in human ovarian carcinoma cells. Anticancer Drugs 6: 405-412, 1995
48. Gispen WH, Hamers FP: Calcium and neuronal dysfunction in peripheral nervous system. Ann NY Acad Sci 747: 419-430, 1994
49. Werth JL, Zhou B, Nutter LM, Thayer SA: 2′,3′-Dideoxycytidine alters calcium buffering in cultured dorsal root ganglion neurons. Mol Pharmacol 45: 1119-1124, 1994
50. Bading H, Segal MM, Sucher NJ, Dudek H, Lipton SA, Greenberg ME: N-methyl-D-aspartate receptors are critical for mediating the effects of glutamate on intracellular calcium concentration and immediate early gene expression in cultured hippocampal neurons. Neuroscience 64: 653-664, 1995
51. Moskowitz PF, Smith R, Pickett J, Frankfurter A, Oblinger MM: Expression of the class III beta-tubulin gene during axonal regeneration of rat dorsal root ganglion neurons. J Neurosci Res 34: 129-134, 1993
52. Alexander JE, Hunt DF, Lee MK, Shabanowitz J, Michel H, Berlin SC, MacDonald TL, Sundberg RJ, Rebhun LI, Frankfurter A: Characterization of posttranslational modifications in neuron-specific class III beta-tubulin by mass spectrometry. Proc Natl Acad Sci USA 88: 4685-4689, 1991
53. Esmaeli-Azad B, McCarty JH, Feinstein SC: Sense and antisense transfection analysis of tau function: tau influences net microtubule assembly, neurite outgrowth and neuritic stability. J Cell Sci 107: 869-879, 1994
54. (2+)-calmodulin regulated effectors of microtubule stability in neuronal tissues. Biochim Biophys Acta 1160: 113-119, 1992